Bruker Corp Stock Price, News & Analysis

Bruker Corporation (NASDAQ: BRKR) showcased its innovative scientific instruments and solutions at Analytica 2022, emphasizing advancements in materials and energy research, as well as biopharmaceuticals. Notable product launches include the HYPERION II FT-IR microscope, TGA II FT-IR module, and DART-EVOQ mass spectrometry system, enhancing analytical capabilities across industries. The introduction of Spatial Single-Cell Metabolomics signifies a leap in cancer research and cell biology. These innovations aim to improve laboratory efficiency and analytical precision for a range of applications.

Bruker Corporation (Nasdaq: BRKR) has launched the NeuraLight 3D Ultra module, enhancing its Ultima multiphoton microscopes for advanced neuroscience and optogenetics research. This module features 3D holographic photostimulation, a larger liquid crystal chip for improved targeting, and a speed of 600 hologram frames per second. It allows researchers to study neural networks more effectively. The NeuraLight 3D Ultra is compatible with newer and selected older Ultima models, promoting innovation in neuroscience research.

Bruker Corporation (Nasdaq: BRKR) showcased innovations at the 70th ASMS Conference, unveiling advancements in spatial multiomics for tissue and tumor microenvironments. The MALDI HiPLEX-IHC technology integrates protein expression profiling with small molecule imaging, enhancing high-plex protein mapping and metabolic process elucidation.

The new microGRID module for the timsTOF fleX platform and SCiLS Lab 2023a software improvements facilitate virtually artifact-free imaging and advanced analytics, positioning Bruker at the forefront of cancer research innovation.

Bruker Corporation has unveiled the timsTOF HT system at the 70th ASMS meeting, enhancing its 4D Multiomics platform with a fourth-generation TIMS XR cell and a 14-bit digitizer. This innovation boosts dynamic range and peptide coverage, enabling the identification of over 100,000 unique peptides with high quantification accuracy. The system supports high-throughput proteomics, achieving sample processing rates of up to 200 samples per day. Additionally, the PaSER mode allows real-time data streaming for intelligent acquisition, further advancing metabolomics and biomarker discovery.

Bruker Corporation (NASDAQ: BRKR) has expanded its mass spectrometry capabilities by acquiring IonSense, the developer of DART™ technology, enhancing Point-of-Need (PoN) analysis. The newly launched DART-EVOQ® triple quadrupole mass spectrometer allows quick analyses across various sectors like food, forensics, and pharmaceuticals without the need for chromatography. Additionally, Bruker has partnered with TOFWERK AG to accelerate the development of high-speed analytical solutions. These strategic moves aim to position Bruker as a leader in PoN mass spectrometry.

Bruker Corporation (Nasdaq: BRKR) will present at the Jefferies 2022 Global Healthcare Conference in New York on June 9, 2022, at 3:00 pm EDT. Frank Laukien, CEO, and Justin Ward, Sr. Director of Investor Relations, will represent the company. A live audio webcast will be available on the Investor Relations section of Bruker's website, with a replay accessible for 30 days post-event. Bruker is dedicated to advancing scientific discovery and enhancing human life through its innovative analytical solutions and high-performance scientific instruments.

Bruker Corporation (NASDAQ: BRKR) announced the approval of a quarterly cash dividend of $0.05 per share. This dividend will be paid on June 17, 2022, to stockholders of record as of June 1, 2022.

Bruker is dedicated to advancing scientific discovery through high-performance instruments and analytical solutions that enhance human life quality. The company operates in various domains including life sciences, applied markets, and industrial applications.

Bruker Corporation (BRKR) has entered a strategic partnership with TOFWERK AG, including a minority investment by Bruker in TOFWERK. This collaboration focuses on enhancing high-speed and ultra-sensitive analytical solutions, particularly in mass spectrometry for small molecules and volatile compounds. The partnership aims to leverage Bruker’s commercial scale to boost TOFWERK’s market presence. Innovations include advanced instrument capabilities and applications for ambient air analysis, breath diagnostics, and semiconductor monitoring.